Safety of proton pump inhibitors: an overview of systematic reviews and meta-analyses

系统回顾 医学 科克伦图书馆 分级(工程) 梅德林 医学物理学 荟萃分析 证据质量 循证医学 质量(理念) 不利影响 患者安全 循证实践 重症监护医学 替代医学 随机对照试验 介绍(产科) 最佳实践 风险分析(工程) 数据质量 干预(咨询)
作者
C M Wang,Huier Gao,Cheng Zhu,Yue Zhao,Yinpeng Qin,Yude Qian,Guodong Feng,Xinran Zhang,Ting Yuan,Fan He,Qianqian Dou,B Y Zhang,Mei Shu,Yi Zhang,Yishan Bu
出处
期刊:BMJ evidence-based medicine [BMJ]
卷期号:: bmjebm-2025
标识
DOI:10.1136/bmjebm-2025-114134
摘要

Background Proton pump inhibitors (PPIs) have been widely used for over 35 years. However, in recent decades, numerous adverse drug reactions (ADRs) have been reported, with evidence often inconsistent and heterogeneous across studies. Objective To conduct an overview of systematic reviews/meta-analyses (SR/MAs) to provide a contemporary review of the evidence for the safety of PPIs in patients using them for treating or prophylaxis, to summarise the outcome data, assess the methodological quality and rate the certainty of the evidence and to provide references for clinical decision-making and the subsequent formulation of evidence. Methods We conducted an overview of reviews following the Preferred Reporting Items for Overviews of Reviews guidelines. We identified SR/MAs regarding PPI safety through a search of multiple databases, including the China National Knowledge Infrastructure, Chinese Science and Technology Journal Database and Wanfang Database (WanFang) on 6 December 2025 as well as Embase, PubMed and the Cochrane Library database on 7 December 2025. The participants were human populations who had been administered PPIs; the intervention groups used PPI-based regimens and the control group received different PPI regimens, no-PPIs, H2-receptor antagonists (H2RAs), potassium-competitive acid blockers (P-CAB) or placebo; the outcomes mainly included the specific ADRs associated with PPI use. We used the A Measurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) tool to assess the methodological quality of the included SR/MAs and employed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to evaluate the quality of evidence for the reported outcomes. The focus of the data presentation was descriptive, featuring detailed tabular presentations of characteristics and results at both the review level and the primary studies level. Main results A total of 940 studies were retrieved from various databases according to the search strategies. After eliminating duplicates and the screening process, 36 SR/MAs were finally included. Overall, there was a slight overlap (corrected covered area, CCA of 0.91%) in 483 primary studies included in the 36 SR/MAs. AMSTAR-2 evaluation results showed that 34 SR/MAs were of low quality, and the other two were of critically low quality. The GRADE evaluation results indicated that the certainty of evidence for all outcomes was low or very low . The use of PPIs might be associated with an increased risk of acute kidney injury (AKI) (relative risk (RR) 1.75, 95% CI 1.40 to 2.19), chronic kidney disease (CKD) (RR 1.35, 95% CI 1.15 to 1.56), gastric cancers (GC) (RR 1.67, 95% CI 1.39 to 2.00) and community-acquired pneumonia (CAP) (OR 1.37, 95% CI 1.22 to 1.53). PPI therapy was associated with a higher recurrence rate of Clostridioides difficile infection (CDI) (24% vs 18%) and might increase CDI risk in renal transplant recipients (RR 2.33, 95% CI 1.07 to 5.07). The use of PPIs might heighten the risk of fractures in young patients (aged <29 years) (RR 1.20, 95% CI 1.12 to 1.29). PPI therapy was also linked to hypomagnesaemia in haemodialysis patients (1/36, 2.78%) and renal transplant recipients (1/36, 2.78%). Conclusions This overview evaluates the safety profile of PPIs, noting associated risks including renal impairment, GC, fractures and infections. Most evidence comes from observational studies, resulting in low or very low certainty evidence that limits definitive causal conclusions. Clinicians and pharmacists may consider greater vigilance with PPI use, and these ADRs may not require de-escalation but de-implementation when inadequate (eg, long-term use or special group use). Future research should focus on high-quality prospective studies and investigate underlying mechanisms to better establish causality and quantify risks. PROSPERO registration number CRD420251059575.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
清梧完成签到,获得积分10
刚刚
Lizhuo完成签到,获得积分10
刚刚
菜头完成签到,获得积分10
刚刚
1秒前
1秒前
小友完成签到 ,获得积分10
1秒前
xsr发布了新的文献求助10
1秒前
小鱼发布了新的文献求助10
1秒前
2秒前
cz完成签到,获得积分10
2秒前
Cordero发布了新的文献求助10
2秒前
2秒前
3秒前
王英霖的应助被hmx采纳,获得10
3秒前
3秒前
貊养浩发布了新的文献求助10
3秒前
山南发布了新的文献求助10
4秒前
4秒前
pg完成签到 ,获得积分10
4秒前
4秒前
上官若男的应助被高大抽屉采纳,获得10
5秒前
5秒前
学生白完成签到,获得积分10
6秒前
清爽的不可完成签到,获得积分10
6秒前
6秒前
6秒前
00hello00完成签到,获得积分10
7秒前
7秒前
小木子完成签到,获得积分10
7秒前
刘泽楷发布了新的文献求助10
7秒前
星辰大海的应助被xinxin采纳,获得10
7秒前
7秒前
貊养浩完成签到,获得积分10
8秒前
思源的应助被搞怪的乐荷采纳,获得10
8秒前
辛勤自行车完成签到,获得积分10
8秒前
maction完成签到,获得积分10
9秒前
灵巧的初阳完成签到,获得积分10
9秒前
zhiruiwang发布了新的文献求助10
10秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188177
求助须知:如何正确求助?哪些是违规求助? 9575987
关于积分的说明 21844723
捐赠科研通 7785975
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482095